G astroesophageal reflux disease (GERD) is a common and chronic condition ranging from mild heartburn to erosive damage of the lining of the esophagus. 1 Medical therapy with proton pump inhibitors (PPIs) results in healing of esophagitis and satisfactory control of heartburn in a majority of patients 2 and represents the initial treatment of choice for patients with GERD. 3 However, PPI therapy is less effective in relieving other symptoms of GERD, such as regurgitation. Kahrilas et al, 4 in a recent systematic review, concluded that the relief of regurgitation with PPI treatment is modest and considerably less than for heartburn. These patients who suffer from regurgitation and other GERD symptoms despite maximum PPI therapy often seek alternative treatment options and may be referred for antireflux surgery (ARS).
The role of gastroesophageal reflux in provoking laryngopharyngeal symptoms is not fully accepted. It is fair to say that multiple studies report that even a high-dose of PPI therapy is not effective in relieving extraesophageal symptoms. [5] [6] [7] [8] [9] [10] ARS has been reported to be effective in relieving these symptoms in single-arm studies, and for this reason, surgical treatment of laryngopharyngeal reflux (LPR) is considered an option by many otolaryngologists for patients who are unsatisfied with medical management. However, as with ARS for patients with typical GERD symptoms, the benefits of ARS surgery must be weighed against the deleterious postfundoplication side effects such as dysphagia, gas bloat syndrome, excess flatulence, inability to belch, and bowel symptoms in those patients with LPR. 11 In the absence of a completely satisfactory treatment, and because the gastroesophageal junction (GEJ) is easily accessible transorally, numerous less invasive, endoluminal procedures have been developed to reconstruct defective gastroesophageal valves.
Transoral incisionless fundoplication (TIF) using the EsophyX 2 device (EndoGastric Solutions, Redmond, WA) offers an alternative, less invasive treatment option for select patients with chronic GERD. The safety and symptomatic outcomes of TIF have been evaluated in numerous retrospective and prospective studies. 2, [12] [13] [14] [15] [16] [17] The most recent multicenter report has demonstrated that the TIF procedure is safe and effective in improving quality of life (QOL) of patients with chronic GERD at 6-month follow-up without introducing the magnitude of deleterious side effects associated with traditional fundoplication. 18 Although the reported outcomes were mostly favorable, important questions about the longerterm outcomes, in comparison with achieved short-term results, have remained.
The primary aim of this study was to evaluate, prospectively, the clinical outcomes of TIF in multicenter community settings at 12-month follow-up. Also, we aimed to conduct a longitudinal analysis of clinical outcomes. We hypothesized that the clinical outcomes would be stable over time and there would be no significant difference in outcomes at 12-compared with the reported outcomes at 6-month follow-up. This study used validated, disease-specific questionnaires to assess GERD symptoms [GERD healthrelated quality of life (GERD-HRQL), reflux symptom index (RSI), and gastroesophageal reflux symptom score (GERSS)]. In addition, esophagogastroduodenoscopy (EGD) was used to evaluate reflux esophagitis and 48-hour pH metry was used to assess intraesophageal pH.
METHODS

Patients
The study population for this report was comprised of the first 100 consecutive patients with GERD who were enrolled in a multicenter registry and underwent TIF with the EsophyX 2 device between January 2010 and February 2011. The study protocol was approved by the local Institutional Review Boards or Western Institutional Review Board (clinical trials.gov: NCT01118585). Approved informed consent was obtained from each patient enrolled in the study after the study conduct was discussed in details.
The patient selection, inclusion and exclusion criteria, study design, and enrollment process have been described previously. 18 Briefly, the study population included patients who suffered from GERD for >1 year and had history of daily PPI use >6 months. All patients had proven GERD demonstrated by abnormal ambulatory pH, esophagitis, peptic strictures, or short segment Barrett esophagus. Exclusion criteria were: (1) hiatal hernia >2 cm in axial length or >3 cm in greatest transverse dimension under full gastric distension, Barrett esophagus >2 cm, body mass index (BMI) >35 kg/m 2 , esophagitis grade D (Los Angeles classification), and presence of other conditions contraindicated with TIF such as gastroparesis, Zenker's diverticulum, achalasia, or scleroderma. 18 Participation in the study was offered to all patients meeting eligibility criteria in an attempt to minimize selection bias.
Preoperative Assessment
Preoperative assessment, described previously, 18 followed the usual clinical protocol for evaluation of chronic GERD patients and included physical exam, ambulatory pH testing off PPIs at centers with available technology, EGD with biopsy to document reflux esophagitis, size of hiatal hernia and characteristics of GEJ (Hill grade), and barium swallow in some cases. Suspicion of achalasia or other motility disorders was an indication for manometry. GERD symptom severity and satisfaction with current health condition were measured by GERD-HRQL, RSI, and GERSS questionnaires. Demographic characteristics, medication use, and GERD history were also recorded at screening. All patients enrolled in this study had objective evidence (abnormal pH, esophagitis, Barrett esophagus, or peptic strictures) of GERD. Twelve patients, from centers where pH testing was not available at the time of screening, were enrolled in the study despite negative endoscopy at screening. 18 However, the previous endoscopies (> 6 months before enrollment in the study) found a small mucosal break in these patients. Indication for surgery of all study patients are shown in Figure 1 .
Operative Technique and Postoperative Care
All operations followed the previously described 2.0 protocol 12, [19] [20] [21] and were performed under general anesthesia. The EsophyX 2 device was gently introduced over the flexible endoscope into the stomach under constant endoscopic visualization. Under continued retroflexed visualization, the helical retractor was engaged into the tissue slightly distal to the Z line. Then, the fundus of the stomach was folded up and around the distal esophagus utilizing the tissue mold and chassis of the device. After locking all the tissue handling elements, the invaginator is activated to allow the separation of the GEJ from the diaphragm. The polypropylene "H" fasteners were delivered through the tissue. The same maneuvers were repeated at 3 additional positions to create full thickness, partial, gastroesophageal fundoplication, 240 to 330 degrees in circumference, 2 to 5 cm long. Valves were created using 12 to 20 fasteners.
Generally, patients were discharged a day after operation. Any prolonged hospitalizations (> 1 d) were recorded and reported as a serious adverse event (SAE). All patients were urged to follow a recommended postoperative diet; a liquid diet for the first 2 weeks followed by 2 weeks of soft diet. After 4 weeks, all patients were instructed to carefully switch to normal eating. Patients were instructed to avoid undertaking rigorous physical activities to prevent disruption of the newly created valve 2 and to continue their PPI medication for 2 weeks to help with potential anxiety and gastric mucosal healing after operation.
Follow-up Assessment
To evaluate symptom resolution and QOL at 12-month follow-up, GERD-HRQL, RSI, and GERSS questionnaires were obtained from 96 of 100 patients. Four patients were lost to follow-up and were excluded from analysis. Patients were asked to undergo EGD or transnasal endoscopy to evaluate healing of esophagitis and elimination or reduction of hiatal hernia. At the centers with available pH technology, patients were asked to undergo 48-hour pH testing to assess the objective outcomes of TIF. Any incidence of de novo dysphagia, bloating, and flatulence were recorded and evaluated. The intraoperative and postoperative SAE were recorded.
Effectiveness Assessments
Symptom evaluation and QOL at 12-month follow-up were assessed with 3 validated disease-specific questionnaires (GERD-HRQL, RSI, and GERSS). The GERD-HRQL questionnaire is a disease-specific questionnaire validated to measure the severity of heartburn (6 questions), dysphagia (2), bloating (1) , and the impact of medication on daily life (1) on the visual analog scale from 0 (no symptoms) to 5 (worst symptoms). Total scores on the GERD-HRQL, calculated per Velanovich, could range from 0 to 50, with the higher scores indicating more severe GERD. 22, 23 Total heartburn score (sum of the first 6 questions on GERD-HRQL) ranges from 0 to 30. Regurgitation scores were assessed with 6 questions similar to those used to assess heartburn and were reported separately from the total GERD-HRQL score. Although this scale is not validated, we elected to report regurgitation results based on this scale to promote consistency with previously published literature on the TIF procedure. RSI is a 9-item evaluation instrument that was developed to measure symptoms associated with LPR. 24 Each item score can range from 0 (no symptoms) to 5 (severe symptoms) with a maximum total score of 45. A total RSI score of r13 is considered normal, whereas patients with a total RSI score >19 are considered likely to have LPR. 25 The GERSS instrument was developed to assess heartburn, regurgitation, abdominal distension, dysphagia, and cough. 26, 27 Specific symptom domains are scored as a product of severity (0 = no symptoms at all to 3 = severe symptoms) and frequency (0 = never to 4 = daily). The total GERSS score ranges from 0 to 60 and represents the sum of individual domain scores ranging from 0 to 12. A total GERSS <18 is considered normal and indicates controlled reflux symptoms with medical or surgical treatment. 27 In this study, the primary effectiveness endpoint was defined as the elimination of daily bothersome typical or atypical symptoms (scores r2 on each question on the GERD-HRQL and RSI) or clinically significant improvement (defined as Z50% reduction in total GERD-HRQL, RSI, and GERSS scores) in global GERD-HRQL, RSI, and GERSS scores.
All 3 questionnaires were administered at baseline, 6-and 12-month follow-up. This allowed us to evaluate the elimination of daily bothersome GERD symptoms at 12-month follow-up compared with baseline on PPIs (primary effectiveness measure) and perform a longitudinal analysis of symptomatic outcomes, healing of esophagitis, PPI use, pH normalization, and incidence of major complications as a measure of safety (secondary effectiveness measures) comparing preoperative, 6-and 12-month data.
PPI consumption was recorded as "none" (medication not taken at all), "occasional" (if any dose was takenr3 d a week) and daily (if any dose was taken > 3 d a week). Complete cessation of PPI at 12-month follow-up was considered clinically significant.
Patient satisfaction with current health condition was assessed as part of the GERD-HRQL questionnaire and was recorded as "satisfied," "neutral," or "dissatisfied."
Endoscopic and 48-hour pH parameters were recorded and compared with baseline measurements in patients willing to undergo endoscopy and pH testing 12 months after TIF. Total esophageal acid exposure was considered normal if pH < 4 occurred for r5.3% of the total 48-hour recording period. 28 Healing of reflux esophagitis was considered clinically significant.
Data Collection
Preoperative, procedure, and postoperative data were collected prospectively by each participating center, entered into the Electronic Data Base (Merge Healthcare) by trained study coordinators and verified for correctness by trained monitors. In an effort to perform a conservative evaluation of the clinical outcomes, specifically the reduction in QOL scores after TIF, the worst effectiveness outcomes observed during the duration of the study (the worst scores, "on daily" PPIs and "dissatisfied" with current health condition) were imputed for 6 patients who underwent reoperation.
Statistical Methods
The Shapiro-Wilk normality test was used to determine whether data were normally distributed. Continuous variables were reported as median and range; categorical data were reported as counts and percent. The nonparametric Wilcoxon-signed rank test was used to assess for statistical significance between 12-month continuous outcomes and baseline values. McNemar and Fisher tests were used to compare proportions of paired and unpaired data. Percentage of patients off PPIs was calculated using the Kaplan-Meier method. A P-value < 0.05 was considered to be statistically significant for all tests. The Friedman test was used to assess changes over time within subjects. To examine where the difference actually occurred, the Wilcoxon-signed rank test with a Bonferroni correction of significant level (P < 0.017 after a correction) on the different combination was used. All statistical analyses were performed with JMP 10.0 software.
RESULTS
Patients
Of 100 patients reported previously at 6-month followup, 18 4 did not return multiple contact attempts, and were considered lost to follow-up. These 4 patients were excluded from 12-month follow-up analysis. In 6 patients, recurrence of severe GERD symptoms, uncontrolled by PPIs, led to a revisional procedure [5 laparoscopic Nissen fundoplication (LNF), 1 TIF]. The worst clinical outcomes observed during the study were assigned to these 6 patients who were considered failures.
All 100 patients had suffered from chronic GERD for a median 9 years (range, 1 to 35 y). Patient characteristics at presentation have been previously described. 18 Briefly, the median age was 53 years (range, 18 to 75 y), BMI ranged from 18.0 to 35.1 kg/m 2 and 65% (65 of 100) were female. All patients were unsatisfied with medical therapy; 92% (92 of 100) of patients experienced daily bothersome GERD symptoms while on daily PPI therapy; the remaining 8 patients had stopped using PPIs because, in their view, medical therapy failed to achieve acceptable symptom control. Esophagitis was present in 52% (52 of 100) of patients and 75 patients had a hiatal hernia [67 of 75 (89%) the hernia axial height was r2 cm; 8 of 75 (11%) had a reducible 2.1 to 3 cm hernia]. The appearance of GEJ was classified as Hill grade I in 6% (5 of 82), Hill grade II in 79% (65 of 82), and Hill grade III in 15% (12 of 82) of patients.
Of 100 patients enrolled, 88% had objectively documented GERD at screening (abnormal pH test, esophagitis, Barrett esophagus, or peptic strictures). The remaining 12 patients, from the centers where pH technology was not available, had a negative endoscopy at screening. However, all 12 had a small mucosal break confirmed with the previous endoscopies more than 6 months before enrollment in the study. 18 These patients were on PPI therapy for a median of 9 years (range, 1 to 15 y). The distribution of abnormal QOL scores preoperatively is shown in Figure 2 .
All procedures were completed successfully without major complications such as esophageal perforation, bleeding requiring transfusion, pneumothorax, and infection of the mediastinal space. No SAEs related to TIF occurred between 6-and 12-month follow-up.
Clinical Outcomes
GERD-HRQL and Heartburn
At 12-month follow-up, in all patients, the median GERD-HRQL improved from 24 (range, 0 to 47) before TIF to 2 (range, 0 to 44), P < 0.001. The median heartburn score fell from 18 (range, 0 to 30) to 1 (range, 0 to 27), P < 0.001. Compared with 6-month follow-up, the 12-month improvement in median total GERD-HRQL score [from 4 (range, 0 to 44) at 6 mo to 2 (range, 0 to 44)] and heartburn scores [from 2 (range, 0 to 25) at 6 mo to 1 (range, 0 to 27)] did not reach statistical significance (P > 0.133 in all cases).
In 85 patients with an abnormal GERD-HRQL score on screening (any score at screening >2), the median score improved from 26 (range, 4 to 47) to 4 (range, 0 to 44), P < 0.001. In 73% of patients (62 of 85) the total GERD-HRQL score at 12-month follow-up was reduced by Z50%; and in 65% (55 of 85) the score normalized (none of the 10 questions on their HRQL >2) indicating elimination of daily bothersome symptoms. The median heartburn score in these patients fell from 19 (range, 0 to 30) to 1 (range, 0 to 27), P < 0.001. In 73% (62 of 85) of patients FIGURE 2. Distribution of preoperative quality-of-life (QOL) scores (scores indicating daily bothersome GERD symptoms) of 100 patients enrolled in the study. GERD-HRQL indicates gastroesophageal reflux disease health-related quality of life; GERSS, gastroesophageal reflux symptom score; RSI, reflux symptom index.
the heartburn score was reduced by Z50%. Daily bothersome heartburn symptoms were eliminated in 78% of patients (66 of 85).
Regurgitation
We evaluated regurgitation symptoms using the same 6 criteria used to determine heartburn symptoms substituting "regurgitation" for "heartburn" in each question. The median regurgitation score of all patients (40 of whom had a normal score at entry) dropped from 15 (range, 0 to 30) to 0 (range, 0 to 25), P < 0.001. The median regurgitation score did not change between 6-and 12-month follow-up, P = 1.0.
Among 58 patients with 12-month follow-up and an abnormal total regurgitation score at entry (at least 1 score >2), 79% (46 of 58) reached a Z50% reduction of their baseline total regurgitation score, and the median regurgitation score improved significantly from 20 (range, 6 to 30) to 0 (range, 0 to 25), P < 0.001. Daily bothersome regurgitation was eliminated in 83% of patients (48 of 58).
GERSS
The median GERSS of all patients fell from 26 (range, 2 to 60) to 4 (range, 0 to 54), P < 0.001. The median GERSS score remained unchanged between 6-and 12-month follow-up (Fig. 3) . Median changes of heartburn, regurgitation, abdominal distension, dysphagia, and cough symptoms as evaluated by GERSS, are shown in Table 1 .
In 59 patients with an abnormal GERSS (> 18) at entry, the median score fell from 35 (range, 19 to 60) to 4 (range, 0 to 54), P < 0.001, unchanged from the 6-month median GERSS score. Eighty-eight percent (52 of 59) of patients normalized their total GERSS score. Fifty-one patients (86%) reached a Z50% reduction of their total GERSS score.
RSI
In all patients, the median total RSI score fell from 20 (range, 0 to 41) to 5 (range, 0 to 44), P < 0.001 at 6-and 12-month follow-up. Median changes of the RSI symptom scores such as hoarseness, troublesome cough, and globus sensation are shown in Table 2 .
Of 74 patients who suffered from any daily bothersome atypical symptom, 72 (97%) completed 12-month follow-up. Sixty-four percent (46 of 72) of patients eliminated their daily bothersome symptoms, and 74% (53 of 72) experienced a Z50% reduction of their total RSI score. In these patients, the median RSI score decreased from 24 (range, 6 to 41) before TIF to 6 (range, 0 to 44), P < 0.001.
Of 67 patients with RSI score >13 at entry, 64 (96%) completed 12-month follow-up. Of these 64 patients, 72% (46 of 64) reached a reduction of their total RSI to r13. In these patients, the median RSI score dropped from 24 (range, 14 to 41) to 6 (range, 0 to 44), P < 0.001.
Patient Satisfaction
Eighty percent of patients at entry were dissatisfied with their current health condition as evaluated by the GERD-HRQL questionnaire. The preoperative median GERD-HRQL score in these patients was 26 (range, 0 to 47); the median heartburn score was 19 (range, 0 to 30). Seventy-six percent of dissatisfied patients had preoperative GERD-HRQL > 20; 12% had GERD-HRQLr12 despite being on daily PPI therapy.
At 12 months after TIF, 15% (14 of 96, P < 0.001), remained dissatisfied (Fig. 4) , unchanged from 6-month results (15% dissatisfied). The median GERD-HRQL of these 14 patients was 15 (range, 0 to 44); the median heartburn score was 1 (range, 0 to 27). Forty-three percent of patients had GERD-HRQLr12 despite answering that they were dissatisfied with their current health and 43% had GERD-HRQL > 20. Five of 14 dissatisfied patients FIGURE 3 . Percentage change in means of gastroesophageal reflux disease health-related quality of life (GERD-HRQL), reflux symptom index (RSI), gastroesophageal reflux symptom score (GERSS), heartburn, and regurgitation scores at 6-and 12-month follow-up compared with baseline. The significant reduction in total scores achieved at 6-month follow-up (P < 0.001 in all cases) remained stable at 12-month follow-up. underwent a revisional procedure and were assigned the worst scores observed during the study.
PPI Consumption
Of 100 patients (92 on daily PPI therapy and 8 who had a history of daily PPI use more than 6 mo but discontinued taking PPIs because the medical therapy failed to achieve acceptable symptom control), 96 completed 12-month follow-up. Seventy-seven percent (74 of 96) of patients were off daily PPI therapy (Fig. 5) . Of 22 patients who were on daily PPIs, 6 underwent a revisional procedure and were considered to be on daily PPI therapy at 12-month follow-up. Seventy-four percent (71 of 96) of patients completely discontinued PPIs, whereas 3% (3 of 96) were taking PPIs occasionally. Kaplan-Meier analysis, based on the date the prescriptions were issued, demonstrated that the majority of patients (20 of 25, 80%) restarted PPIs within 6 months after the procedure (Fig. 6) .
The proportion of patients resuming PPI therapy did not significantly change between 6-and 12-month follow-up; from 20% at 6-month to 26% at 12-month follow-up, P > 0.05.
Of 8 patients who discontinued taking PPIs because, in their view, they had no symptomatic improvement before TIF, 7 (88%) were completely free of PPIs at 12 months and their daily bothersome GERD symptoms were completely eliminated as evaluated by the 3 questionnaires. In 1 patient, the GERD symptoms were controlled with daily PPI therapy. Only 1 patient remained dissatisfied with current health condition compared with 8 dissatisfied before TIF. None of these patients underwent revision.
Of these 8 patients, 6 underwent preoperative pH testing and were objectively confirmed to have abnormal distal esophageal acid exposure. Three of these 6 repeated pH testing at 6-or 12-month follow-up and had normalized % total time pH < 4. Two patients had peptic structures, The values represent medians (range). At 6-month follow-up, 90% (90 of 100) and at 12-month follow-up 80% (80 of 100) of patients completed RSI questionnaire off PPIs.
P-values represent comparison between 12-month follow-up versus pre-TIF. PPI indicates proton pump inhibitors; RSI, reflux symptom index; TIF, transoral incisionless fundoplication.
FIGURE 4. Patient satisfaction with current health condition as evaluated by gastroesophageal reflux disease health-related quality-oflife (GERD-HRQL) questionnaire. Eighty percent of patients at entry were dissatisfied with their current health condition; at 12 months only 15% (14 of 96; 4 patients were lost to follow-up at 12 mo, P < 0.001), remained dissatisfied, unchanged from 6-month results (15% dissatisfied). Five of 14 dissatisfied patients underwent a revisional procedure and were assigned the worst scores observed during the study.
confirmed with preoperative EGD. In addition, 4 patients suffered from severe atypical symptoms as indicated by the total RSI score >13. Moreover, 5 patients had abnormal GERD-HRQL (at least 1 score >2). Overall, in this subgroup of patients, the median duration of prior PPI use was 4 years (range, 1 to 18 y); the median GERD duration was 8 years (range, 2 to 18 y). Of 19 patients who remained on PPI therapy and who did not undergo a revisional procedure, 15 (79%) were on the same dose as before TIF, 3 (16%) lowered their dose and 1 (5%) started daily PPI therapy after being off medication before the procedure. Even though these patients remained on PPIs, TIF was still associated with an improved QOL; the median heartburn score was reduced from 14 (range, 3 to 30) to 6 (range, 0 to 27), P < 0.001; and the median regurgitation score was reduced from 10 (range, 0 to 30) to 1 (range, 0 to 25), P = 0.001.
Endoscopic Assessment
Of 100 patients treated, 50 were willing to undergo endoscopic evaluation at 12-month follow-up. The mean length (2.8, SD 0.6 cm) and circumference (245, SD 45 degrees) of fundoplication were virtually unchanged from the same parameters observed at 6 months. Hiatal hernia present at screening was reduced in 81% (29/36) , with complete reduction in 69% (25 of 36) of patients. De novo hiatal hernia developed in 2 patients. In the remaining 5 patients, the axial length of hiatal hernia remained the same (3 patients) or increased by 1 cm (2 patients).
Esophagitis was present in 52 patients at preoperative screening. As most screening was performed with patients on PPIs (or off for a week if pH testing performed at time of endoscopy), this incidence level was not surprising. Seventeen patients with esophagitis at screening underwent 12-month follow-up endoscopy. Esophagitis healed in 76% (13 of 17) and improved in additional 12% (2 of 17). One patient showed worsening of esophagitis from LA grade A to B and 1 patient remained unchanged. The proportion of patients with healed esophagitis remained stable over time (75% at 6 mo and 76% at 12 mo).
pH Outcomes
All 44 patients who underwent ambulatory pH testing at screening had abnormal esophageal acid exposure. Twenty-seven (61%) repeated the 48-hour pH metry 12 months after the procedure. Of these 27, 14 (52%) demonstrated normalization of esophageal acid exposure with r5.3% total time pH < 4. Of 28 patients who underwent pH testing at 6-month follow-up, 21 patients underwent the same test 12 months after TIF. The proportion of patients with normalized % total time was 54% (15 of 28) at 6-month and not significantly different from 43% (9 of 21) at 12-month follow-up, P = 0.567. Five patients (24%) who had normal % total time at 6-month follow-up had abnormal pH test at 12-month follow-up. Three patients (14%) normalized % total time after having abnormal values at 6-month follow-up.
Furthermore, a separate analysis of patients who underwent pH testing at 6-and 12-month follow-up versus those who did not have pH testing revealed interesting findings. All median QOL scores (GERD-HRQL, RSI, and GERSS) were nominally lower in patients who did not undergo pH testing at 6-and 12-month follow-up (Table 3) . Altogether, this indicates that patients who had better outcomes did not have pH testing at 6-and 12-month follow-up.
Postfundoplication Side Effects
Dysphagia, bloating, and flatulence median scores across the entire study group improved significantly compared with baseline and remained stable compared with scores at 6-month follow-up. Median dysphagia score was improved from 1 (range, 0 to 5) pre-TIF to 0 (range, 0 to 5) at 12-month follow-up; median bloating score was improved from 2 (range, 0 to 5) to 0 (range, 0 to 5), P < 0.001 in both cases. At 12-month follow-up, 2 patients reported de novo dysphagia and 1 patient reported de novo bloating (scores went from 0 before TIF to 3 at 12-mo follow-up), maximum score of 5 indicates the most severe symptoms. Excess flatulence score improved significantly from 2 (range, 0 to 5) pre-TIF to 0 (range, 0 to 5), P < 0.001; 2 patients reported worsening flatulence (scores went from 2 before TIF to 3 at 12-mo follow-up). patients were lost to follow-up at 12 mo) of patients were off daily PPI therapy at 12-month follow-up. Six of 22 patients who were back on PPI therapy underwent a revisional procedure and were considered to be on daily PPI therapy at 12-month follow-up. 
Revisions
Six patients underwent reoperation (5 LNF, 1 TIF) between 8 and 11 months after the original procedure. All 6 patients were on daily PPIs before TIF. Five of 6 (83%) were female and 2 of 6 (33%) had BMI > 30. In these patients, at screening while on PPIs, the median total GERD-HRQL was 34 (range, 22 to 45); heartburn score was 26 (range, 16 to 30). Four of 6 had total GERD-HRQL score >30; the other 2 patients had total score of 29 and 22. Furthermore, the median total RSI score was 22 (range, 12 to 41); 4 of 6 had total RSI > 13. Of these 6 patients, 3 (50%) underwent preoperative pH testing and had abnormal % total time pH < 4; the median was 11 (range, 10 to 16). Of other 3 patients, 2 had esophagitis LA grade A at screening endoscopy and 1 had a small mucosal break as confirmed with an endoscopy more than 6 months before procedure. Endoscopic evaluation, 6 months after the procedure, revealed small hiatal hernia (r2 cm) in 2 patients who did not have a hiatal hernia at screening. Four of 6 patients who underwent pH testing before revisional procedure had abnormal % total time pH < 4. One patient who failed had a 3 cm hiatal hernia at screening. One patient had severe vomiting after the procedure and 2 patients did not follow the recommended postoperative diet.
DISCUSSION
The principal finding in this study is that the outcomes observed at 6-month follow-up remained stable across a range of evaluation methodologies at 12-month follow-up. The observed median GERD-HRQL [4 (range, 0 to 44) at 6 mo vs. 2 (range, 0 to 44) at 12 mo], RSI [5 (range, 0 to 45) at both follow-up visits], GERSS [4 (range, 0 to 44) at both follow-up visits], heartburn [2 (range, 0 to 25) at 6 mo vs. 1 (range, 0 to 27) at 12 mo], and regurgitation scores [0 (range, 0 to 25) at both follow-up visits] remained the same or slightly improved between 6-and 12-month follow-up. Similar to total scores, median scores of the specific symptom scores were unchanged between 6-and 12-month follow-up (Tables 1 and 2 ). The percentage of patients who completely ceased PPI consumption decreased slightly from 80% at 6-month to 74% at 12 months after procedure, P > 0.05. The 6 patients who underwent revisions were included in the analyses and were assigned daily PPI use. Furthermore, the proportion of patients with healed esophagitis (76% at 12 mo vs. 75% at 6 mo) remained virtually unchanged. Observed results indicate the durability of treatment response from 6 to 12 months after TIF and this represents the most important finding of this study.
Since the introduction of TIF with the EsophyX device in 2007, several reports have demonstrated the safety of TIF and suggested its effectiveness in controlling typical and atypical GERD symptoms and healing of esophagitis. 2, [13] [14] [15] [16] [17] 19, 20 Most of these reports were retrospective in nature, had short-term follow-up, were from centers outside of the United States and may have reflected a period of technique development. In contrast, this study reports the outcomes of a prospective, multicenter US study of the TIF procedure performed by surgeons and gastroenterologists already experienced in the more developed technique, 2.0 protocol. The 2.0 technique, which creates an esophagogastric rather than a gastrogastric fundoplication, has been demonstrated to provide better reflux control than the original technique. 12 Despite the fact that this study was not randomized and that patients served as their own controls, well-defined inclusion/exclusion criteria, multicenter study design, large sample size, and medium-term follow-up provided a picture of TIF as a clinically viable and more durable procedure than may commonly be believed.
Regurgitation is a typical GERD symptom that is the least well-controlled by medical therapy and is very wellcontrolled by traditional antireflux procedures. 11 At this juncture, TIF also has been reported to result in a resolution of daily bothersome regurgitation. Trad et al, 2 in a single-center retrospective study, found that regurgitation was eliminated in 80% of patients at a median of 14 months (range, 3 to 29 mo) after the procedure. In another retrospective study, Barnes and Hoddinott 15 reported that significantly fewer patients complained about troublesome regurgitation at a median of 7 months (range, 5 to 17 mo). The current study demonstrated elimination of daily bothersome regurgitation in 83% of patients at 12-month follow-up, which is clinically meaningful, especially in light of the near absence of side effects.
Interestingly, heartburn was also a frequent breakthrough symptom in our patients on medical therapy before TIF. The median heartburn score of patients with typical GERD symptoms on PPIs before TIF was high [19 (range, 0 to 30)] indicating severe heartburn. The elimination of daily bothersome heartburn after TIF was achieved in 78% of patients and approached the degree of relief seen with regurgitation.
The role of GERD in development of extraesophageal symptoms remains a topic of debate. LPR symptoms such The values represent medians (range). At 6-month follow-up, 90% (90 of 100) and at 12-month follow-up 80% (80 of 100) of patients completed quality-oflife questionnaires off PPIs.
P-values represent comparison between patients with pH test versus patients without pH test at 6-and 12-month follow-up. GERD-HRQL indicates gastroesophageal reflux disease health-related quality of life; GERSS, gastroesophageal reflux symptom score; PPI, proton pump inhibitors; RSI, reflux symptom index; TIF, transoral incisionless fundoplication.
as persistent cough, hoarseness, and globus sensation have been associated with GERD in some studies. 29, 30 On the basis of these studies, many ENT specialists have a heightened awareness of the potential association between reflux and otherwise unexplained laryngeal symptoms. Multiple single-arm studies have demonstrated that laparoscopic fundoplication results in eliminating troublesome LPR symptoms in 48% to 65% of patients with documented GERD. [31] [32] [33] In a small concurrent controlled study, Swoger et al 34 found that surgical fundoplication did not improve laryngeal symptom reliably in patients previously unresponsive to aggressive acid suppression. In this current study, elimination of chronic daily bothersome atypical symptoms after TIF, measured using a standardized LPR questionnaire (RSI), was achieved in a majority of patients (64%). Furthermore, the improvement in median scores seen across all symptom domains (Table 2 ) at 6-month follow-up remained stable over time, indicating that TIF may be viewed as an alternative treatment option for patients with chronic extraesophageal manifestations of GERD. Future studies, focused on patients with extraesophageal manifestation of GERD, may help define the role of TIF in the management of LPR patients.
TIF has been found to have extremely low rates of de novo dysphagia, bloating, and excess flatulence in multiple studies. 2, 13, 16, 19 In this study, the median scores for dysphagia, bloating, and flatulence were significantly reduced. Two patients reported de novo dysphagia (that did not require any treatment), and only 1 patient reported de novo bloating (scores 0 to 3). Although TIF has not been compared with LNF in any single study, these rates are lower than those reported from single-arm studies of LNF. Even though some minimize the significance of these side effects, the recently published 5-year results from Long-Term Usage of Esomeprazole versus Surgery for Treatment of Chronic GERD (LOTUS) trial indicate that the prevalence of dysphagia (11% vs. 5%), bloating (40% vs. 28%), and flatulence (57% vs. 40%) was significantly higher in the laparoscopic ARS group than in the esomeprazole group. 35 The very low risk of TIF-related side effects, in combination with an excellent safety profile, suggests that TIF may be a valid treatment option for patients not willing to accept the side-effect profile and risks associated with LNF. However, patients should be informed that the extent of primary symptom improvement after TIF is less than improvement seen with traditional ARS. Also, currently, long-term data beyond 14-month follow-up are only available from initial European trials which assessed previous iteration of the TIF technique.
In our previous report 18 we identified that a GERD-HRQL score r30 before TIF was associated with successful outcomes of TIF. Although factors associated with successful outcomes or failures of TIF were not an endpoint in this study, it is worth noting that 4 of 6 patients who underwent a revisional procedure had a total GERD-HRQL score >30 (scores: 31, 37, 38, and 45) while on PPIs, and that 1 of the 6 patients who underwent revision had a total GERD-HRQL score of 29 at screening. This patient also had a BMI of 33.9 at screening and suffered from severe heartburn and regurgitation. This patient underwent LNF and subsequent to that operation developed a paraesophageal hernia. One patient had experienced severe vomiting after TIF not requiring hospitalization and afterwards developed de novo hiatal hernia. Although patient selection criteria continue to evolve, the current study suggests that a preoperative GERD-HRQL score over 30 on PPIs and postoperative vomiting are associated with a poorer outcome.
Analysis of 19 patients who continued taking any dose of PPIs and who did not undergo revision, revealed significant reduction in total GERD-HRQL, heartburn, regurgitation, and RSI scores. Although these patients are back on PPIs, our data suggest that TIF made a therapeutic impact and improved symptomatic control. Patients should be informed that additional post-TIF management of the disease with antisecretory medications may be required to fully control chronic GERD symptoms in some cases.
The 6 reoperations were performed without difficulties. The surgical field of the EGJ in patients who underwent TIF had few adhesions. 36 Our experience with reoperations after TIF confirms the previous report that the presence of previous TIF does not seem to make revisional LNF more technically complicated than LNF without prior TIF. 36 Although the results of this study further support the viability of TIF in the management of chronic GERD, this report has limitations. First, this was an observational, nonrandomized, open-label study. Second, a limited number of patients underwent pH testing both before TIF and 12 months after procedure. Third, the duration of followup was limited to 12 months. Forty-four patients included in this report underwent pH testing before TIF. However, it is worth noting that all patients included in this report had objective evidence of GERD (esophagitis, abnormal pH test, peptic strictures, and/or Barrett esophagus). Ambulatory pH testing before TIF has a value and should be used to confirm GERD in symptomatic patients in absence of esophagitis or other objective evidence of the disease. With regard to post-TIF pH testing, the goals of GERD treatment are to improve QOL and to heal esophagitis, when present. 37 Normalization of esophageal acid exposure has been used to compare various GERD treatment modalities; however, the clinical value of pH normalization in patients with mild to moderate disease is unclear. Seventeen to 80% patients rendered asymptomatic on PPIs continue to have abnormal amounts of esophageal acid exposure. [38] [39] [40] [41] Postoperative pH testing has a role in evaluating patients with persistent or recurrent symptoms after ARS. It remains unclear whether the abnormal pH test in patients rendered symptom-free after TIF adds meaningful value to disease management. Our critical look at patients who underwent pH testing at follow-up visits versus patients who did not have pH testing indicated that patients with better outcomes (lower QOL scores) did not undergo postoperative pH testing. Therefore, the possible selection bias regarding patients who underwent post-TIF pH testing was minimal, if any. With regard to duration of follow-up, we are currently accumulating data for the same population at 2-and 3-year follow-up and will report the outcomes at a later time. In addition, to our knowledge, 2 randomized-controlled trials are currently underway.
The future role of TIF in treating chronic GERD will be judged by its power to control bothersome symptoms long-term with minimal postfundoplication side effects, and by its ability to maintain an excellent safety profile. Current published literature points toward careful patient selection, good technique, and rigorous postprocedure management for the first 6 weeks after procedure. The physicians performing this procedure see the rationale for TIF in low complication rate, acceptable symptomatic control, increased satisfaction with current health, improved QOL, and the near-absence of postfundoplication symptoms which leads to excellent patient satisfaction. The results presented here suggest that limiting TIF to patients with less severe disease may reduce the need for a revisional procedure. Alternative treatment modalities such as LNF may be considered for the most severe GERD patients with hiatal hernias >2 cm in axial length.
In conclusion, this study presents the US experience of a cohort of 100 patients receiving TIF, with the longest multicenter follow-up from the United States to date. In this study, TIF provided a safe and effective therapeutic option for carefully selected chronic GERD patients with unsatisfactory medical management. Although pH normalization was achieved in a limited number of patients, QOL was improved and daily bothersome symptoms were eliminated in up to 82% of patients. The majority of patients (78%) were off daily PPIs at 12-month follow-up. Further randomized-controlled studies will define more completely the role of TIF in the management of chronic GERD.
